Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered ...

Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.08 or 1.14% from the prior close of $7.02. The stock opened at $7.02 and touched ...

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of opportunities, ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own ...

The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.22 apiece, ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Biogen Inc. is fending off a lawsuit in the Delaware Chancery Court over its recent offer to buy out Sage Therapeutics, its ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...